Poster: Drug/Disease modeling - Absorption & PBPK Archives - PAGE Meeting (Population Approach Group Europe)

Assessment of DDI potential of ruxolitinib (INC424), a dual substrate of CYP3A4 and CYP2C9, using a verified PBPK model to support submissions to Health Authorities

Thursday 16 October, 2025

Objectives: With the physiologically-based pharmacokinetic (PBPK) model, the drug-drug interaction (DDI) potential of ruxolitinib for CYP3A4 and CYP2C9 was evaluated at…

Physiologically-Based Pharmacokinetic (PBPK) Modeling of the Dronedarone Drug-Drug Interaction with Digoxin

Thursday 16 October, 2025

Objectives: Dronedarone is the strongest known perpetrator drug to evaluate the impact of P-gp inhibition on P-gp substrates (victim drugs)…

Physiologically-based Pharmacokinetic Modeling of Rifampin Drug-Drug Interactions with Midazolam and Digoxin

Thursday 16 October, 2025

Objectives: Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict the magnitude of drug-drug interactions (DDIs)…

Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis

Thursday 16 October, 2025

Objectives: Sepsis is characterized by an excessive release of inflammatory mediators substantially affecting body composition and organ function further augmented…

Application of Simcyp® simulator platform for the assessment of the pharmacokinetic profile of Gd-DOTA regarding its disposition in brain tumors lesions with different vasculature

Thursday 16 October, 2025

Objectives:Gadolinium based contrast agents (GBCA) are used in dynamic –contrast enhanced magnetic resonance imaging (DCE-MRI) for diagnosis of lesions such…

A Mechanistic multicompartmental Pharmacokinetic model for food effect of fenofibrate

Thursday 16 October, 2025

Objectives: Fenofibrate is a prodrug of the active metabolite fenofibric acid and it is used for hypercholesterolemia and hypertriglyceridemia. Absorption…

Use of a physiologically-based pharmacokinetic modelling and simulation approach to rationalise actinomycin D dosing in paediatric oncology

Thursday 16 October, 2025

Purpose: To use physiologically-based pharmacokinetic (PBPK) modelling and simulation in the prediction of the pharmacokinetics of actinomycin D in children,…

Physiologically based pharmacokinetic model incorporating genetic polymorphism of CYP2D6 to predict the nonlinear kinetics of paroxetine

Thursday 16 October, 2025

Background: Paroxetine exposure increases more than linear with increasing doses and with decreasing number of active CYP2D6 alleles, which precludes…

Pharmacokinetics of Sulfadoxine and Pyrimethamine for intermittent preventive treatment of malaria during Pregnancy and after delivery.

Thursday 16 October, 2025

Objectives: Sulfadoxine/pyrimethamine (SP) is recommended for intermittent preventative (IPT) treatment of malaria during pregnancy. In this work, we present a secondary…

Model-based comparison of modified-release metoprolol formulations in beagle dogs and rabbits

Thursday 16 October, 2025

Objectives: Metoprolol, a selective adrenergic β1-receptor antagonist, is commonly prescribed for a variety of cardiovascular conditions. This drug is available…